CytRx Corporation to Present at Roth Capital Partners New York Conference

Strategic Insights -

CytRx Corporation's President and CEO, Steven Kriegsman, will present at the Roth Capital Partners New York Conference on September 14, 2004, highlighting the company's key technologies, including RNAi development programs in ALS, obesity/type 2 diabetes, and CMV, as well as an update on the Phase I HIV DNA Vaccine trial. The conference will be webcast live, providing a comprehensive overview of CytRx's research and development endeavors.

Key Takeaways:

  • CytRx Corporation, a biopharmaceutical research and development company, will present at the Roth Capital Partners New York Conference on September 14, 2004.
  • The presentation will cover the company's key technologies, including RNAi development programs in ALS, obesity/type 2 diabetes, and CMV, as well as an update on the Phase I HIV DNA Vaccine trial.
  • CytRx has a strategic alliance with the University of Massachusetts Medical School to develop novel compounds using RNAi technology.
  • The company has a research program with Massachusetts General Hospital, Harvard University's teaching hospital, to use RNAi technology to develop a drug for ALS.
  • CytRx has licensed its TranzFect delivery technology for DNA-based vaccines for certain diseases.
  • The average stock price of the 94 presenting companies at the 2003 Roth Capital Partners New York Conference rose 31.04% between September 5, 2003 and July 2, 2004.
  • The conference will be webcast live, providing a comprehensive overview of CytRx's research and development endeavors.

Statistics:

  • CytRx's RNAi development programs are being conducted in collaboration with the University of Massachusetts Medical School.
  • The Phase I HIV DNA Vaccine trial is being conducted in conjunction with Advanced Bioscience Laboratories and the University of Massachusetts Medical School.
  • The 2003 Roth Capital Partners New York Conference showcased 94 companies to an audience of over 650 institutional investors.
  • The average stock price of the 94 presenting companies at the 2003 conference rose 31.04% between September 5, 2003 and July 2, 2004.

Sources:

  • CytRx Corporation, http://www.cytrx.com/
  • Roth Capital Partners, http://www.rothcp.com/
  • University of Massachusetts Medical School, http://www.umassmed.edu/
  • Massachusetts General Hospital, http://www.massgeneral.org/